Cabaletta Bio, Inc. (CABA)
Nasdaq: CABA · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2018
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Mar 23, 2026 | Mar 31, 2025 | Mar 21, 2024 | Mar 16, 2023 | Mar 17, 2022 | Mar 16, 2021 | Mar 30, 2020 | · |
| Research and development | 142,674 | 97,203 | 55,424 | 39,300 | 32,494 | 21,376 | 11,671 | 4,467 |
| General and administrative | 29,567 | 27,938 | 19,236 | 14,839 | 13,819 | 12,457 | 7,012 | 1,726 |
| Total operating expenses | 172,241 | 125,141 | 74,660 | 54,139 | 46,313 | 33,833 | 18,683 | 6,193 |
| Operating income | -172,241 | -125,141 | -74,660 | -54,139 | -46,313 | -33,833 | -18,683 | -6,193 |
| Interest expense | 2,004 | 748 | 0 | · | · | · | · | · |
| Interest and investment income | 6,031 | 10,025 | 6,985 | 1,164 | 24 | 494 | 1,740 | 235 |
| Income tax expense | 0 | 0 | · | · | · | · | · | · |
| Net income including non-controlling interests | -167,856 | -115,864 | -67,675 | -52,975 | -46,289 | -33,339 | -16,943 | -12,202 |
| Net income | -167,856 | -115,864 | -67,675 | -52,975 | -46,289 | -33,339 | -16,943 | -12,202 |
| Net income to common shareholders | · | · | · | · | · | -33,339 | -22,269 | -12,202 |
| Earnings per share, basic | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 | · | · | · |
| Earnings per share, diluted | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.80 | -1.44 | -4.07 | -6.87 |
| Weighted average shares, basic | · | · | 1,168,054 | 5,942,036 | · | · | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic